Late-onset schizophrenia is relatively common. Onset after the age of 40 years is reported in 23% of patients hospitalised with schizophrenia. The condition is different from early-onset schizophrenia on a number of counts, including the response to antipsychotic drugs. This Cochrane review set out to assess the effects of antipsychotic drugs for elderly people with [read the full story…]
There has been concern about the rate of use of antipsychotic mecdication for people with learning disabilities for some time. We have posted a number of studies which have raised questions about efficacy and rate of use here on this blog. The authors of this study were concerned to look at prescription rates in people [read the full story…]
Mental Elf readers have been voting for their favourite topics and top of the list at present are psychological therapies and depression. Us elves like to give people what they want, so here’s a review conducted by researchers in the Netherlands that summarises what we know about the effectiveness of different types of psychotherapy in [read the full story…]
This new systematic review compares how effective first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs) are at preventing relapse in patients with schizophrenia. The authors carried out a meta-analysis of 23 randomised controlled trials that lasted for ≥6 months and compared FGAs with SGAs in schizophrenia. The outcomes they studied were: Study defined relapse Relapse at 3, [read the full story…]
A multidisciplinary group of Dutch scientists have produced a guideline to help diagnose and treat medically unexplained physical symptoms (MUPS) and somatoform disorders (SD) in primary care, hospitals and occupational health settings. The guideline summarises the best available evidence and attempts to answer 4 key questions, for which the following findings are presented: 1. Preventive [read the full story…]
In 2004 the US Food and Drug Administration published a “black box” warning that highlighted an increased risk of suicide and suicidal thoughts in young people who were taking antidepressants. This warning was updated in 2007. A new analysis of 41 randomised controlled trials has been published in the Archives of General Psychiatry, which suggests [read the full story…]
There’s an interesting review in the British Journal of Psychiatry this week, which compares the effectiveness of psychiatric drugs with those used to treat physical health problems. The headline from the review is that ‘psychiatric drugs are as effective as other drugs’. Professor Stefan Leucht who led the review team claims that: There is a [read the full story…]
Lithium is a medicine that has been used for over 50 years to treat depression and bipolar disorder. It comes in two forms that are used clinically: lithium carbonate and lithium citrate. A certain level of the drug is needed in the blood stream for it to be effective, but if the level rises too [read the full story…]
The Whole System Demonstrator programme is the largest randomised control trial of telehealth and telecare in the world. One of the most complex trials ever undertaken by the Department of Health, it was set up in May 2008 to provide a clear evidence base to support investment decisions. The research proposition was : Does the [read the full story…]
About 1 in 1000 susceptible patients suffers from aggressive periodontitis. Sufferers have more rapid gingival attachment loss with some losing more that half their bony support by 35. This can be localised to a small number of teeth or more generalised. The aim of this study was to evaluate the adjunctive clinical and microbiological effects [read the full story…]
